KarMMa-9 Trial Design Disclosed; Plans to Accelerate Cell Therapy Development in Multiple Autoimmune Diseases; Innovative and Diverse Preclinical Pipeline Presented; BMS’s 2023 R&D Day Summary

On Thursday, September 14, BMS held its 2023 R&D day (press release / presentation) disclosing Abecma’s (BMS / 2seventy’s BCMA CAR-T) Ph3 KarMMa-9 trial design in HR NDMM. The company also highlighted its plans to initiate BMS-986393’s (CC-95266; GPRC5D CAR-T) registrational trial in H1 2024 as well as its intention to submit an IND for the investigation of BMS-986353 (CC-97540 CD19 NEX-T CAR-T) in multiple sclerosis (MS) in September 2023. Additionally, BMS shared its full cell therapy pipeline, including highly innovative and diverse preclinical assets. Below, Celltelligence provides insights on KarMMa-9 design and the company’s new GPRC5D x BCMA dual targeting CAR-T for MM, while discussing BMS’s market opportunity in the autoimmune disease cell therapy space.

About The Author

The Celltelligence Team

Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.


You’ll be able to access the full article from your Celltelligence Library after signing up.